Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0222
EDITORIAL
|
Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome?
|
|
| |
Since there is no abstract available we provide the first paragraph.
With isolated success – trastuzumab, imatinib, vemurafenib-, the current generation of targeted drugs provides limited benefit for cancer patients. Evidence from phase 3 randomized trials suggests mostly progression-free survival benefit without a true overall survival prolongation. The advent of high-throughput technologies and advances in systems computational biology shape now high expectations for the next-generation cancer-targeted drugs and biomarkers. This new era of personalized medicine raises hope for individual tumor-heterogeneity-based implementation of targeted drugs. Which are the challenges and how could be possible to overcome therapeutic resistance of cancer cells and to increase cancer therapy efficacy and improve oncological outcomes?
(Citation: Gastric & Breast Cancer 2011; 11(2): 53-57)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 23 April 2012 |
|
